RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,085,514 | +17.9% | 664,773 | +15.1% | 0.00% | 0.0% |
| Q2 2023 | $4,313,515 | +20.9% | 577,445 | +7.9% | 0.00% | 0.0% |
| Q1 2023 | $3,569,297 | -20.6% | 535,127 | -8.2% | 0.00% | 0.0% |
| Q4 2022 | $4,494,945 | +18.0% | 583,002 | +62.8% | 0.00% | 0.0% |
| Q3 2022 | $3,809,000 | +138.7% | 358,066 | +82.6% | 0.00% | – |
| Q2 2022 | $1,596,000 | +6.5% | 196,067 | -6.4% | 0.00% | – |
| Q1 2022 | $1,499,000 | -29.2% | 209,409 | +69.4% | 0.00% | – |
| Q4 2021 | $2,117,000 | +393.5% | 123,586 | +562.1% | 0.00% | – |
| Q3 2021 | $429,000 | +6.7% | 18,667 | +69.5% | 0.00% | – |
| Q2 2021 | $402,000 | – | 11,013 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
| Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
| MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
| Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
| ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
| MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
| Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
| Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |